Guidant Corp. v. St. Jude Medical, Inc.

409 F. Supp. 2d 543, 79 U.S.P.Q. 2d (BNA) 1165, 2006 U.S. Dist. LEXIS 286, 2006 WL 38925
CourtDistrict Court, D. Delaware
DecidedJanuary 6, 2006
DocketCiv. 04-0067-SLR
StatusPublished

This text of 409 F. Supp. 2d 543 (Guidant Corp. v. St. Jude Medical, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Guidant Corp. v. St. Jude Medical, Inc., 409 F. Supp. 2d 543, 79 U.S.P.Q. 2d (BNA) 1165, 2006 U.S. Dist. LEXIS 286, 2006 WL 38925 (D. Del. 2006).

Opinion

MEMORANDUM OPINION

ROBINSON, Chief Judge.

I. INTRODUCTION

On February 2, 2004, Guidant Corporation and its subsidiaries Cardiac Pacemakers, Inc. and Guidant Sales Corporation, along with co-plaintiff Mirowski Family Ventures, L.L.C. (collectively called “plaintiffs”), filed the present action against St. Jude Medical, Inc. and Pacesetter, Inc. (collectively called “defendants”), alleging infringement of U.S. Patent No. Re 38,-119E (the “ ’119 reissue patent”). (D.I.l)

On April 19, 2005, the court granted St. Jude’s motion for leave to file an early summary judgment motion on recapture. Before the court is defendants’ motion for summary judgment that the ’119 reissue patent is invalid under the recapture rule. (D.I.90)

II. BACKGROUND

A. Technology

The technology of the accused products involves cardiac resynchronization therapy (CRT) for the treatment of congestive heart failure. (D.I. 91 at 3) CRT works to ensure that the lower chambers of the heart — the right ventricle and the left ventricle — contract synchronously with each other in order to maximize the flow of blood through the heart and body. Id The CRT devices and methods accused in this action focus on synchronizing the ventricles by applying low-voltage electrical stimulation to both ventricles. This is often referred to as “bi-ventricular pacing.” Id

Bi-ventricular pacing can be accomplished by connecting leads to an implantable pulse generator and then lacing the *545 other ends of the leads — which contain one or more electrodes — in or on the chambers of the heart, including the ventricles. The electrodes are used to stimulate the ventricles, but they may also be used to sense naturally occurring cardiac depolarization signals in the heart. Sensing such depolarization signals can be used by the CRT device in connection with the delivery of resynchronizing stimulating pulses. Id. at 3-4.

The 119 reissue patent is a reissue of U.S. Patent No. 4,928,688 (the ’688 patent”). The ’688 patent claims are directed to an invention where the sensed depolarization signals are “analyzed” and the electrodes, depending on the sensed depolarization signals, stimulate the ventricles (“conditional embodiment”). The 119 reissue patent claims are directed to an invention where the sensed signals are not “analyzed,” but rather the electrodes are stimulated unconditionally (“unconditional embodiment”). Plaintiffs allege that defendants infringe the 119 patent by making and selling congestive therapy products that provide cardiac resynchronization therapy (“CRT”) to treat CHF. 1 (D.I.28)

On January 23, 1989, the original ’688 patent application was filed with the Patent and Trademark Office (PTO) and assigned patent application number 07/299895 (“the ’895 application”). (D.I. 91, ex. A at 1)

On June 9, 1989, the PTO examiner issued his first action, rejecting claims 1-14 and 17-22 of the ’895 application. (D.I. 91, ex A at 42) The examiner allowed claims 15 and 16. (Id.) Claims 2, 3, 8 and 9 were rejected as being obviousness in view of Nappholz 2 and Cohen. 3 (Id. at 43) According to the examiner, Cohen showed “a means to sense a cardiac signal from the left or right ventricles [and it would be] obvious to use Cohen with the pacemaker in Nappholz ... to more efficiently and effectively pace and sense the heart.” (Id. at 44) The examiner explicitly noted that “the prior art does not show means to sense and stimulate both ventricles in a selective or alternate manner.” (Id. at 44)

In response to the examiner’s rejections of claims 1, 4-7 and 12-14, Dr. Morton M. Mower, the listed inventor, argued:

[I]t is clear that the method being claimed involves detecting the respective cardiac signals originating in the left and the right ventricles of the heart. After analyzing those cardiac signals (or the absence thereof) in an electronic control circuit, electrical pulses are provided from a stimulating circuit to one, the other or both ventricles for effecting substantially simultaneous contraction of both ventricles. Clearly, Nappholz does not teach this method. The Nappholz patent describes a ... pacemaker having a single atrial electrode and a single ventricular electrode.... Thus, the device of that patent is incapable of picking up ventricular depolarization signals from both ventricles and ultimately for providing stimulation to both ventricles.

(D.I. 91, ex. A at 49-50) (emphasis in original) With respect to claims 7, 12-14, Dr. Mower argued that they were distinguishable over Nappholz because they called for “sensing cardiac signals originating in the atrium, in both ventricles and then stimulating both ventricles in a fashion such that simultaneous contraction of the ventricles occurs after a predeter *546 mined A-V delay period.” {Id. at 50) According to this argument, Nappholz cannot simultaneously sense or pace in both ventricles. {Id.) With respect to claims 2, 3, 8 and 9, Dr. Mower asserted that they were not obvious in light of Nappholz and Cohen. {Id. at 51) Nappholz disclosed a pacemaker that sensed and selectively paced an atria and sensed and selectively paced a ventricle. {Id.) The Cohen prior art reference, Dr. Mower argued, had electrodes in the ventricles that paced but did not sense. {Id.) Thus, the two references did not suggest

the idea of placing sensing electrodes in both the left and right ventricles and providing a control circuit capable of detecting the depolarization signals from both the left and right ventricles and to then provide control signals to a stimulating circuit that is used to stimulate one, the other or both ventricles whereby substantially simultaneous contraction of both ventricles ... results.

{Id.)

In response to these arguments, the examiner allowed claims 4 and 15-22, but rejected claims 7-9, 13 and 14 as being anticipated by Rockland 4 which, it was asserted, disclosed the structure of these claims. (D.I. 91, ex. A at 54) Claims 1, 2, 3 and 5 were rejected over Rockland because it would be “within the scope of the skilled artisan when utilizing the Rockland ... invention.” {Id. at 56) Claims 10, 23 and 25-27 were rejected as being obvious in light of Rockland and Funke, 5 as it would be “an obvious engineering design choice ... to connect the ventricular electrodes in series, as shown by Funke.” {Id.) Claims 11 and 24 were rejected because “[i]t would have been obvious to one of ordinary skill in the art to use McCorkle 6 with Rockland ... and Funke in order to more efficiently and accurately pace/sense ventricular depolarizations.” {Id.)

Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Ball Corporation v. The United States
729 F.2d 1429 (Federal Circuit, 1984)
In Re Elmar W. Weiler and Richard L. Mansell
790 F.2d 1576 (Federal Circuit, 1986)
In Re Sarah C. Watkinson
900 F.2d 230 (Federal Circuit, 1990)
Westvaco Corporation v. International Paper Company
991 F.2d 735 (Federal Circuit, 1993)
Southwall Technologies, Inc. v. Cardinal Ig Company
54 F.3d 1570 (Federal Circuit, 1995)
In Re Clement
131 F.3d 1464 (Federal Circuit, 1998)
Hester Industries, Inc. v. Stein, Inc., Defendant-Cross
142 F.3d 1472 (Federal Circuit, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
409 F. Supp. 2d 543, 79 U.S.P.Q. 2d (BNA) 1165, 2006 U.S. Dist. LEXIS 286, 2006 WL 38925, Counsel Stack Legal Research, https://law.counselstack.com/opinion/guidant-corp-v-st-jude-medical-inc-ded-2006.